We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-6.91%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$488M
AUM Growth
-$65.2M
Cap. Flow
-$17.8M
Cap. Flow %
-3.65%
Top 10 Hldgs %
32.78%
Holding
126
New
4
Increased
19
Reduced
35
Closed
4

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$5.8M
2
INCY icon
Incyte
INCY
+$5.8M
3
BCR
CR Bard Inc.
BCR
+$5.67M
4
AKRX
Akorn Inc
AKRX
+$4.79M
5
EW icon
Edwards Lifesciences
EW
+$3.89M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$6.82M
2
ILMN icon
Illumina
ILMN
+$5.64M
3
AMSG
Amsurg Corp
AMSG
+$4.79M
4
SYK icon
Stryker
SYK
+$2.92M
5
CI icon
Cigna
CI
+$2.88M

Sector Composition

Rank Sector Weight
1 Healthcare 91.87%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$23.1M 4.73%
199,650
+5,400
+3% +$601K
SYK icon
2
Stryker
SYK
$123B
$18.6M 3.81%
155,400
-25,400
-14% -$2.92M
MDT icon
3
Medtronic
MDT
$106B
$18.5M 3.79%
259,500
+12,000
+5% +$943K
UNH icon
4
UnitedHealth
UNH
$387B
$17.6M 3.61%
110,000
+10,800
+11% +$1.61M
ABT icon
5
Abbott
ABT
$175B
$15.6M 3.19%
405,500
+21,500
+6% +$853K
INCY icon
6
Incyte
INCY
$23.4B
$15.1M 3.09%
150,400
+59,400
+65% +$5.8M
BIIB icon
7
Biogen
BIIB
$30.4B
$13.9M 2.85%
49,000
-5,500
-10% -$1.63M
GILD icon
8
Gilead Sciences
GILD
$167B
$12.9M 2.63%
179,500
+23,000
+15% +$1.71M
LGND icon
9
Ligand Pharmaceuticals
LGND
$6.08B
$12.7M 2.59%
199,622
+28,293
+17% +$1.79M
AMGN icon
10
Amgen
AMGN
$198B
$12.2M 2.5%
83,500
– –
BSX icon
11
Boston Scientific
BSX
$65.4B
$11.9M 2.44%
550,000
-25,000
-4% -$545K
REGN icon
12
Regeneron Pharmaceuticals
REGN
$70.9B
$11.9M 2.43%
32,300
-5,700
-15% -$2.17M
EW icon
13
Edwards Lifesciences
EW
$49.4B
$11.7M 2.4%
375,000
+120,000
+47% +$3.89M
BCR
14
DELISTED
CR Bard Inc.
BCR
$11.5M 2.35%
51,100
+26,100
+104% +$5.67M
ZBH icon
15
Zimmer Biomet
ZBH
$17.6B
$10.6M 2.18%
106,090
+23,690
+29% +$2.54M
AKRX
16
DELISTED
Akorn Inc
AKRX
$10M 2.06%
460,000
+208,000
+83% +$4.79M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.5B
$9.14M 1.87%
83,800
– –
VTRS icon
18
Viatris
VTRS
$20.1B
$8.99M 1.84%
235,700
– –
HOLX
19
DELISTED
Hologic
HOLX
$8.81M 1.8%
219,600
-22,500
-9% -$868K
CNC icon
20
Centene
CNC
$32.8B
$8.57M 1.75%
303,260
+20,400
+7% +$602K
TEVA icon
21
Teva Pharmaceuticals
TEVA
$37.3B
$8.52M 1.74%
234,990
+47,800
+26% +$1.91M
BAX icon
22
Baxter International
BAX
$11.7B
$8.43M 1.73%
190,000
– –
ILMN icon
23
Illumina
ILMN
$28.2B
$6.89M 1.41%
55,306
-41,814
-43% -$5.64M
BDX icon
24
Becton Dickinson
BDX
$43.6B
$6.62M 1.36%
41,000
-15,375
-27% -$2.55M
AGN
25
DELISTED
Allergan plc
AGN
$6.17M 1.26%
29,400
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2016 Portfolio in Review

As of Q4 2016, Bellevue Group held 126 positions worth $488M, down 12% from $553M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group withdrew a net $17.8M in Q4 2016, closing 4 positions and reducing 35 holdings. Its most notable exit was Amsurg Corp, an estimated $4.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Danaher worth $5.76M.

  • Bellevue Group's largest Q4 2016 buy was Danaher: 83,472 shares worth $5.76M.
  • Bellevue Group added most to Incyte in Q4 2016, an estimated $5.8M increase.
  • Bellevue Group's biggest Q4 2016 reduction was Cardinal Health, cutting an estimated $6.82M.
  • Bellevue Group fully exited Amsurg Corp in Q4 2016, selling an estimated $4.79M.
  • Bellevue Group's ten largest holdings make up 33% of its $488M portfolio in Q4 2016.
  • Bellevue Group opened 4 new positions and closed 4 in Q4 2016.
  • Bellevue Group's portfolio value fell 12% quarter-over-quarter to $488M.

Based on Bellevue Group's 13F filing for Q4 2016, filed 10 Feb 2017.